Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O5 |
Molecular Weight | 270.2369 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O
InChI
InChIKey=TZBJGXHYKVUXJN-UHFFFAOYSA-N
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
DescriptionSources: https://www.drugbank.ca/drugs/DB01645Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15909536 | https://www.ncbi.nlm.nih.gov/pubmed/28265354 | https://www.ncbi.nlm.nih.gov/pubmed/25996650 | https://clinicaltrials.gov/ct2/show/NCT01664650
Sources: https://www.drugbank.ca/drugs/DB01645
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15909536 | https://www.ncbi.nlm.nih.gov/pubmed/28265354 | https://www.ncbi.nlm.nih.gov/pubmed/25996650 | https://clinicaltrials.gov/ct2/show/NCT01664650
GENISTEIN is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1806 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7769390 |
0.11 µM [IC50] | ||
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17574424 |
6.8 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibitory effect of natural and environmental estrogens on thymic hormone production in thymus epithelial cell culture. | 1999 Dec |
|
Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. | 2000 Jul-Aug |
|
Differential induction of tumor necrosis factor alpha and manganese superoxide dismutase by endotoxin in human monocytes: role of protein tyrosine kinase, mitogen-activated protein kinase, and nuclear factor kappaB. | 2000 Mar |
|
Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha. | 2000 Sep |
|
Tyrosine kinase inhibitors against EGF receptor-positive malignancies. | 2001 |
|
FAK induction in keratinocytes in an in vitro model of reepithelialization. | 2001 Apr |
|
Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. | 2001 Apr |
|
PTH stimulates PLCbeta and PLCgamma isoenzymes in rat enterocytes: influence of ageing. | 2001 Feb |
|
Genistein potentiates the radiation effect on prostate carcinoma cells. | 2001 Feb |
|
Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. | 2001 Feb |
|
Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. | 2001 Feb 15 |
|
Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogen-activated protein kinase cascades. | 2001 Feb 15 |
|
Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. | 2001 Feb 16 |
|
Molecular biology of transplant arteriosclerosis and sites of therapeutic intervention. | 2001 Feb-Mar |
|
Effects of tyrosine kinase inhibitors on cell death induced by sodium fluoride and pertussis toxin in the pancreatic beta-cell line, RINm5F. | 2001 Jan |
|
Interleukin-6 up-regulates the oxytocin receptor in cultured uterine smooth muscle cells. | 2001 Mar |
|
Ca(2+)-dependent production of reactive oxygen metabolites by human neutrophils in response to fluorinated propranolol analogues. | 2001 Mar 1 |
|
Dihydropyridine calcium channel blockers inhibit ascorbic acid accumulation in human intestinal Caco-2 cells. | 2001 Mar 2 |
|
Effects of simple aromatic compounds and flavonoids on Ca2+ fluxes in rat pituitary GH(4)C(1) cells. | 2001 Mar 2 |
|
The "in vivo" and "ex vivo" roles of cylcooxygenase-2, nuclear factor-kappaB and protein kinases pathways in the up-regulation of B1 receptor-mediated contraction of the rabbit aorta. | 2001 Mar 2 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01664650
54 mg/day in 2 tablets for 12 months.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28265354
Cells were cultured in Dulbecco’s modified Eagle’s medium (U2OS, HCT116) media containing fetal calf serum, penicillin, streptomycin, glutamine, nonessential amino acids (Hyclone). The long-term growth curves of both 10 μmol/L genistein-treated U2OS and HCT116 cells were then determined by MTS assay. The experiment was conducted for 60 days with measuring the population doublings (PD) every 2–4 days after each dilution.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
||
|
NCI_THESAURUS |
C1821
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
241107
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
||
|
NCI_THESAURUS |
C599
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
||
|
DSLD |
1584 (Number of products:80)
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1288816
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
28088
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
m5696
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
GENISTEIN
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
DB01645
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
D019833
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
36586
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
207-174-9
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
DH2M523P0H
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
DH2M523P0H
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
C1113
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
5280961
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
SUB13958MIG
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
100000078160
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
11073
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
27514
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
7475
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
446-72-0
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
DTXSID5022308
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY | |||
|
FG-12
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | |||
|
25696
Created by
admin on Fri Dec 15 15:53:45 GMT 2023 , Edited by admin on Fri Dec 15 15:53:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
74224
Created by
admin on Fri Dec 15 15:53:44 GMT 2023 , Edited by admin on Fri Dec 15 15:53:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)